Arrhythmias & electrophysiologyRandomised controlled trial
Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial
- Randomised controlled trial
- phase 2
- investigator-initiated
- multicentre
- double-blind
- placebo-controlled
Authors' conclusion
In patients with frequent symptomatic PACs, memantine reduced atrial ectopy and atrial tachyarrhythmia burden and demonstrated a favorable safety profile.
Study context
- Population
- Symptomatic adults with frequent premature atrial contractions (PACs ≥1000/24 h)efficacy analysis
- Participants
- 241 adults
- Comparison
- Memantine vs placebo
- Primary endpoint
- Percentage change in mean 24-hour PAC count from baseline
- Follow-up
- End of treatment (6 weeks)
Primary result
Percentage change in mean 24-hour PAC count · end of treatment
Between-group difference
47.1 percentage points
P = 0.0045
As reported in the abstract
Secondary outcomes
Responder rate (≥50% PAC reduction)
P < 0.0001
Cumulative incidence of new-onset AF
P < 0.0001
| Outcome | between-group difference (percentage points) | P value |
|---|---|---|
| Nonsustained atrial tachycardia burden (percentage change) · reduced with memantine | 30.98 | P = 0.0043 |
Safety
ECG intervals, LV function, drug-related serious adverse events
- No clinically meaningful differences in ECG intervals or LV function
- No drug-related serious adverse events
Original publication
Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. Circulation. Published 19 March 2026. doi:10.1161/circulationaha.125.079023
Summarised from the published abstract; every number is checked against it